Cell cycle dysregulation in pituitary oncogenesis

Frontiers of Hormone Research

Volumn 32, Issue , 2004, Pages 34-62

  Muşat, Madalina ^a,b   Vax, Vladimir V ^b   Borboli, Ninetta ^b   Gueorguiev, Maria ^b   Bonner, Sarah ^b   Korbonits, Márta ^b   Grossman, Ashley B ^b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR PROTEIN;

ANIMAL; CELL CYCLE; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; CELL CYCLE; HUMANS; NEOPLASM PROTEINS; PITUITARY NEOPLASMS;

EID: 4043083605     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000079037     Document Type: Article

References (169)

1. Morgan DO: Cyclin-dependent kinases: Engines, clocks and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-291.
2. Vidal A, Koff A: Cell-cycle inhibitors: Three families united by a common cause. Gene 2000; 247:1-15.
3. Morgan D, Murray A, Hunt T, Nurse P: The cell cycle and programmed cell death; in Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (eds): Molecular Biology of the Cell. New York, Garland Science, 2002, pp 983-1026.
4. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993;7:812-821.
5. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, et al: Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex. Nature 1995;376:313-320.
6. Pines J, Hunter T: Isolation of a human cyclin cDNA: Evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989;58:833-846.
7. Fisher RP, Morgan DO: A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994;78:713-724.
8. Akoulitchev S, Chuikov S, Reinberg D: TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 2000;407:102-106.
9. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY: Human retinoblastoma susceptibility gene: Cloning, identification and sequence. Science 1987;235:1394-1399.
10. Lee WH, Shew JY, Hong FD, Sery TW, Donoso LA, Young LJ, et al: The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987; 329:642-645.
11. Zhu L, van den HS, Helin K, Fattaey A, Ewen M, Livingston D, et al: Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 1993;7:1111-1125.
12. Yeung RS, Bell DW, Testa JR, Mayol X, Baldi A, Grana X, et al: The retinoblastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19. Oncogene 1993;8:3465-3468.
13. Mayol X, Grana X, Baldi A, Sang N, Hu Q, Giordano A: Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 1993;8: 2561-2566.
14. Morris EJ, Dyson NJ: Retinoblastoma protein partners. Adv Cancer Res 2001;82:1-54.
15. Weintraub SJ, Prater CA, Dean DC: Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992;358:259-261.
16. Bremner R, Cohen BL, Sopta M, Hamel PA, Ingles CJ, Gallie BL, et al: Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 1995;15:3256-3265.
17. Bosco G, Du W, Orr-Weaver TL: DNA replication control through interaction of E2F-RB and the origin recognition complex. Nat Cell Biol 2001;3:289-295.
18. Paggi MG, Baldi A, Bonetto F, Giordano A: Retinoblastoma protein family in cell cycle and cancer: A review. J Cell Biochem 1996;62:418-430.
19. Sala A, Nicolaides NC, Engelhard A, Bellon T, Lawe DC, Arnold A, et al: Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells. Cancer Res 1994;54:1402-1406.
20. Zhu L, Zhu L, Xie E, Chang LS: Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. Mol Cell Biol 1995;15:3552-3562.
21. Moberg K, Starz MA, Lees JA: E2F-4 switches from p130 to p107 and pRB in response to cell cycle re-entry. Mol Cell Biol 1996;16:1436-1449.
22. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.
23. Cress WD, Seto E: Histone deacetylases, transcriptional control and cancer. J Cell Physiol 2000; 184:1-16.
24. Lipinski MM, Jacks T: The retinoblastoma gene family in differentiation and development. Oncogene 1999;18:7873-7882.
25. Lipinski MM, Macleod KF, Williams BO, Mullaney TL, Crowley D, Jacks T: Cell-autonomous and non-cell-autonomous functions of the Rb tumor suppressor in developing central nervous system. EMBO J 2001;20:3402-3413.
26. Hickman ES, Moroni MC, Helin K: The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 2002;12:60-66.
27. Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999;287:821-828.
28. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
29. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-261.
30. Harper JW: Cyclin-dependent kinase inhibitors. Cancer Surv 1997;29:91-107.
31. Nakayama K, Nakayama K: Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development. Bioessays 1998;20:1020-1029.
32. Coqueret O: New roles for p21 and p27 cell-cycle inhibitors: A function for each cell compartment? Trends Cell Biol 2003;13:65-70.
33. Uhlmann F, Lottspeich F, Nasmyth K: Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1. Nature 1999;400:37-42.
34. Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418-422.
35. Kakar SS, Jennes L: Molecular cloning and characterization of the tumor transforming gene (TUTR1): A novel gene in human tumorigenesis. Cytogenet Cell Genet 1999;84:211-216.
36. Vousden KH, Lu X: Live or let die: The cell's response to p53. Nat Rev Cancer 2002;2:594-604.
37. Melino G, De Laurenzi V, Vousden KH: p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002;2:605-615.
38. Yang A, McKeon F: P63 and P73:P53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000;1: 199-207.
39. Irwin MS, Kaelin WG: p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001;12:337-349.
40. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G: The p53/p63/p73 family of transcription factors: Overlapping and distinct functions. J Cell Sci 2000;113:1661-1670.
41. Balint EE, Vousden KH: Activation and activities of the p53 tumour suppressor protein. Br J Cancer 2001;85:1813-1823.
42. Donnellan R, Chetty R: Cyclin D1 and human neoplasia. Mol Pathol 1998;51:1-7.
43. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, et al: Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clin Cancer Res 1999;5:2133-2139.
44. Farrell WE, Clayton RN: Molecular pathogenesis of pituitary tumors. Front Neuroendocrinol 2000;21:174-198.
45. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, et al: A p16INK4ainsensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.
46. Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, et al: Genetic testing for melanoma. Lancet Oncol 2002;3:653-654.
47. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, et al: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7:209-216.
48. Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M, Barbacid M: Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 2001; 20:6637-6647.
49. Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN, et al: Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 2001;22: 1149-1154.
50. Vax V, Bibi R, Diaz-Cano S, Gueorguiev M, Kola B, Bressac-de Paillerets B, et al: Activating point mutations in cyclin-dependent kinase 4 (CDK4) are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. J Endocrinol 2003;178:301-310.
51. Ceha HM, Nasser I, Medema RH, Slebos RJ: Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein. Biochem Biophys Res Commun 1998; 249:550-555.
52. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY: Heterozygous Rb-1 δ 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994;9:1021-1027.
53. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 1992;359:295-300.
54. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D: Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995;55:1613-1616.
55. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, et al: Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997;82:818-824.
56. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN, et al: Chromosome 13q deletion mapping in pituitary tumors: Infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Res 1999;59: 1562-1566.
57. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE: Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000;60: 1211-1216.
58. Asa SL, Ezzat S: The pathogenesis of pituitary tumours. Nat Rev Cancer 2002;2:836-849.
59. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
60. Woloschak M, Yu A, Post KD: Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog 1997;19:221-224.
61. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE: Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer 1999;24: 328-336.
62. Ruebel KH, Jin L, Zhang S, Scheithauer BW, Lloyd RV: Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas. Endocr Pathol 2001;12:281-289.
63. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, et al: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3633.
64. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
65. Frost SJ, Simpson DJ, Clayton RN, Farrell WE: Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line. Mol Endocrinol 1999;13:1801-1810.
66. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, et al: CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998;12:2899-2911.
67. Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y: Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000;20:6147-6158.
68. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-684.
69. Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, et al: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-158.
70. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 1994;14:3683-3694.
71. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
72. Kobayashi H, Montgomery KT, Bohlander SK, Adra CN, Lim BL, Kucherlapati RS, et al: Fluorescence in situ hybridization mapping of translocations and deletions involving the short arm of human chromosome 12 in malignant hematologic diseases. Blood 1994;84:3473-3482.
73. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, et al: Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995;55:1206-1210.
74. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9: 1149-1163.
75. Sherr CJ, Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
76. Philipp-Staheli J, Payne SR, Kemp CJ: p27(Kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001;264:148-168.
77. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996;382:325-331.
78. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al: The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571-1583.
79. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, et al: A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997;14:2283-2289.
80. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P: Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57:5441-5445.
81. Carneiro C, Jiao MS, Hu M, Shaffer D, Park M, Pandolfi PP, et al: p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development. Oncogene 2003;22: 361-369.
82. Kerbel RS, St Croix B, Florenes VA, Rak J: Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell 1996;9:257-264.
83. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, et al: Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade. Mol Cell 1998;1:553-563.
84. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor-β-arrested epithelial cells. Mol ell Biol 1994;14:3683-3694.
85. Kato A, Takahashi H, Takahashi Y, Matsushime H: Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. J Biol Chem 1997;272: 8065-8070.
86. Huang S, Chen CS, Ingber DE: Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. Mol Biol Cell 1998;9:3179-3193.
87. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS: E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998;142:557-571.
88. Boehm M, Nabel EG: Cell cycle and cell migration: New pieces to the puzzle. Circulation 2001; 103:2879-2881.
89. Shimada Y, Gulli MP, Peter M: Nuclear sequestration of the exchange factor Cdc24 by Far1 regulates cell polarity during yeast mating. Nat Cell Biol 2000;2:117-124.
90. Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML: Inactivation of p27Kip1 by the viral E1A oncoprotein in TGF-β-treated cells. Nature 1996;380:262-265.
91. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P: Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996; 13:2323-2330.
92. Schuchner S, Wintersberger E: Binding of polyomavirus small T antigen to protein phosphatase 2A is required for elimination of p27 and support of S-phase induction in concert with large T antigen. J Virol 1999;73:9266-9273.
93. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y: Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 1997;15:629-637.
94. Varshavsky A: The ubiquitin system. Trends Biochem Sci 1997;22:383-387.
95. Terrell J, Shih S, Dunn R, Hicke L: A function for monoubiquitination in the internalization of a G protein-coupled receptor. Mol Cell 1998;1:193-202.
96. Spence J, Gali RR, Dittmar G, Sherman F, Karin M, Finley D: Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 2000;102:67-76.
97. Russell SJ, Reed SH, Huang W, Friedberg EC, Johnston SA: The 19S regulatory complex of the proteasome functions independently of proteolysis in nucleotide excision repair. Mol Cell 1999;3: 687-695.
98. Muratani M, Tansey WP: How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003;4:192-201.
99. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, et al: Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 1999;274:13886-13893.
100. Yu ZK, Gervais JL, Zhang H: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 1998;95:11324-11329.
101. Yam CH, Ng RW, Siu WY, Lau AW, Poon RY: Regulation of cyclin A-Cdk2 by SCF component Skp1 and F-box protein Skp2. Mol Cell Biol 1999;19:635-645.
102. Marti A, Wirbelauer C, Scheffner M, Krek W: Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999;1:14-19.
103. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK: Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001;413:311-316.
104. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001;413: 316-322.
105. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, et al: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294:173-177.
106. Nguyen H, Gitig DM, Koff A: Cell-free degradation of p27(kip1), a G1 cyclin-dependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 1999;19:1190-1201.
107. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997;11:1464-1478.
108. Vlach J, Hennecke S, Amati B: Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997;16:5334-5344.
109. Muller D, Thieke K, Burgin A, Dickmanns A, Eilers M: Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pore-associated protein mNPAP60. EMBO J 2000;19: 2168-2180.
110. Claret FX, Hibi M, Dhut S, Toda T, Karin M: A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996;383:453-457.
111. Scheffner M: Moving protein heads for breakdown. Nature 1999;398:103-104.
112. Tomoda K, Kubota Y, Kato J: Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999;398:160-165.
113. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, et al: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13:1181-1189.
114. Swanson C, Ross J, Jackson PK: Nuclear accumulation of cyclin E/Cdk2 triggers a concentrationdependent switch for the destruction of p27Xic1. Proc Natl Acad Sci USA 2000;97:7796-7801.
115. Chamovitz DA, Segal D: JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2001;2:96-101.
116. Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama K: Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001;276:48937-48943.
117. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM, et al: A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 2001;413:323-327.
118. Bloom J, Pagano M: Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-47.
119. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, et al: A growth factordependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 2002;21:3390-3401.
120. Fujita N, Sato S, Katayama K, Tsuruo T: Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002;277:28706-28713.
121. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, et al: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-1144.
122. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8: 1153-1160.
123. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al: PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-1152.
124. Reed SI: Cell cycling? Check your brakes. Nat Cell Biol 2002;4:E199-E201.
125. Soucek T, Yeung RS, Hengstschlager M: Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998;95:15653-15658.
126. Clurman BE, Porter P: New insights into the tumor suppression function of P27(kip1). Proc Natl Acad Sci USA 1998;95:15158-15160.
127. Yang HY, Zhou BP, Hung MC, Lee MH: Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 2000;275:24735-24739.
128. Millard SS, Vidal A, Markus M, Koff A: A U-rich element in the 5′-untranslated region is necessary for the translation of p27 mRNA. Mol Cell Biol 2000;20:5947-5959.
129. Kullmann M, Gopfert U, Siewe B, Hengst L: ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′-UTR. Genes Dev 2002;16:3087-3099.
130. Sgambato A, Cittadini A, Faraglia B, Weinstein IB: Multiple functions of p27(Kip1) and its alterations in tumor cells: A review. J Cell Physiol 2000;183:18-27.
131. Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000;404:782-787.
132. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, et al: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275:24500-24505.
133. Trapasso F, Iuliano R, Boccia A, Stella A, Visconti R, Bruni P, et al: Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol 2000;20:9236-9246.
134. Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H, et al: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol 2001;11:263-267.
135. Qian X, Jin L, Kulig E, Lloyd RV: DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 1998;153:1475-1482.
136. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-744.
137. Knudson AG Jr: Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
138. Takeuchi S, Bartram CR, Wada M, Reiter A, Hatta Y, Seriu T, et al: Allelotype analysis of childhood acute lymphoblastic leukemia. Cancer Res 1995;55:5377-5382.
139. Hatta Y, Yamada Y, Tomonaga M, Koeffler HP: Extensive analysis of the retinoblastoma gene in adult T-cell leukemia/lymphoma. Leukemia 1997;11:984-989.
140. Kibel AS, Freije D, Isaacs WB, Bova GS: Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999;25:270-276.
141. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A: p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 1999;96:6382-6387.
142. Tanaka C, Yoshimoto K, Yang P, Kimura T, Yamada S, Moritani M, et al: Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J Clin Endocrinol Metab 1997;82:3141-3147.
143. Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, Lowe DG, et al: Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998;16:69-76.
144. Qian X, Jin L, Grande JP, Lloyd RV: Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 1996;137:3051-3060.
145. Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W, et al: Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas. Eur J Endocrinol 1999;140:250-255.
146. Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, et al: Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors and malignant pituitary tumors. J Clin Endocrinol Metab 1999;84:3823-3830.
147. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, et al: Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002;87:2635-2643.
148. Pyle ME, Korbonits M, Gueorguiev M, Jordan S, Kola B, Morris DG, et al: Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol 2003; 176:103-110.
149. Musat M, Korbonits M, Pyle M, Gueorguiev M, Kola B, Morris DG, Powell M, Dumitrache C, Poiana C, Grossman AB: The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors. Pituitary 2002;5:235-242.
150. Musat M, Korbonits M, Kola B, Morris DG, Coculescu M, Dumitrache C, et al: Over-expression of Akt (protein kinase B, PKB) mRNA in pituitary tumors (abstract). ENDO 2003.
151. Kakar SS, Chen L, Puri R, Flynn SE, Jennes L: Characterization of a polyclonal antibody to human pituitary tumor transforming gene 1 (PTTG1) protein. J Histochem Cytochem 2001;49: 1537-1546.
152. s152 Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, et al: Pituitary tumor transforming gene expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761-767.
153. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
154. Buckley N, Bates AS, Broome JC, Strange RC, Perrett CW, Burke CW, et al: P53 protein accumulates in Cushing's adenomas and invasive non-functional adenomas. J Clin Endocrinol Metab 1995;80:4.
155. Levy A, Hall L, Yeudall WA, Lightman SL: p53 gene mutations in pituitary adenomas: Rare events. Clin Endocrinol (Oxf) 1994;41:809-814.
156. Herman V, Drazin NZ, Gonsky R, Melmed S: Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-55.
157. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
158. Schoonjans K, Martin G, Staels B, Auwerx J: Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-166.
159. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of 9-cis-retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771-774.
160. Heaney AP, Fernando M, Yong WH, Melmed S: Functional PPAR-receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002;8:1281-1287.
161. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE: Peroxisome proliferator-activated receptor ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells. J Biol Chem 2000;275:22435-22441.
162. Sugimura A, Kiriyama Y, Nochi H, Tsuchiya H, Tamoto K, Sakurada Y, et al: Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 1999;261:833-837.
163. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y: Activation of peroxisome proliferatoractivated receptor-by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000;60:5558-5564.
164. Heaney AP, Fernando M, Melmed S: PPAR-receptor ligands: Novel therapy for pituitary adenomas. J Clin Invest 2003;111:1381-1388.
165. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, et al: KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294:2563-2566.
166. Reeves HL, Arthur MJP, Oginbiyi OA, Narla G, Goldberg S, Harpaz N, et al: The role of Krüppellike factor 6 (KLF6) in colorectal neoplasia (abstract). Association of Physicians, Annual General Meeting, 2003.
167. Vax V, Gueorguiev M, Lane T, Dedov I, Grossman AB, Korbonits M: Polymorphism of the Krüppellike transcription factor 6 (KLF6) gene in sporadic pituitary tumors. Endocr Relat Cancer 2003; 11:397-402.
168. Zhong W, Feng H, Santiago FE, Kipreos ET: CUL-4 ubiquitin ligase maintains genome stability by restraining DNA-replication licensing. Nature 2003;423:885-889.
169. Nakayama KI, Hatakeyama S, Nakayama K: Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001;282:853-860.